An Ex-Commissioner’s Bleak Take On The State Of Biopharma Innovation
Executive Summary
Former US FDA Commissioner Robert Califf remains eager to encourage broader use of real-world evidence – but his blunt, pessimistic read on the state of biopharma innovation is remarkable coming from a former FDA head.
You may also be interested in...
BIO 2022 Notebook: Future Directions For R&D
News and views from day four of the BIO annual meeting include a fireside chat with FDA commissioner Robert Califf, gene therapy insights, and pharma efforts to provide cancer medicines in lower income countries.
BIO 2022 Notebook: Future Directions For R&D
News and views from day four of the BIO annual meeting include a fireside chat with FDA commissioner Robert Califf, gene therapy insights, and pharma efforts to provide cancer medicines in lower income countries.
Geriatric Exclusivity? Incentives For Research In Elderly Debated At National Academies Workshop
FDA principal deputy commissioner Amy Abernethy and former commissioner Robert Califf point to success of orphan drug and pediatric exclusivity incentives in spurring drug development for neglected populations.